Shortcuts

open access

Vol 8, No 1 (2012)
Prace oryginalne
Published online: 2012-04-26
Get Citation

Evaluation of plasminogen activator inhibitor 1 concentration in patients with simple obesity

Paweł Bogdański, Monika Szulińska, Joanna Dytfeld, Danuta Pupek-Musialik
Endokrynol. Otył. Zab. Przem. Mat 2012;8(1):1-7.

open access

Vol 8, No 1 (2012)
Prace oryginalne
Published online: 2012-04-26

Abstract

INTRODUCTION. Relationship between obesity and atherosclerosis development is well-documented. Among risk factors of atherosclerosis progression are both „old” and „new” — which clinical value is still intensively studied. In the pathogenesis of increased procoagulat state observed in obese patients potential role of plasminogen activator inhibitor 1 (PAI-1) is analysed. The aim of the study was to evaluate PAI-1 concentration and its relationship with selected anthropometric and biochemical parameters.
MATERIAL AND METHODS. 88 obese patients and 25 healthy subjects as a control were studied. Anthropometric parameters, concentrations of: fasting glucose, lipids, insulin with use of radioimmunomethric method, tumor necrosis factor alpha (TNFa) and PAI-1 with use of immunoenzymatic method were assessed. Insulin resistance in the participants was evaluated according to the homeostasis model assessment–insulin resistance (HOMA-IR) protocol.
RESULTS. Serum concentrations TNFa, PAI-1 and HOMA-IR index were significantly higher in the studied group as compared to the control. Positive correlation between insulin concentration, HOMA-IR and PAI-1 were found.
CONCLUSIONS. 1. Obese patients characterise increased activation of inflammatory process, procoagulant predisposition and insulin resistance. 2. In the pathogenesis of increased procoagulant activity in obese patients, observed in our study as elevated PAI-1 concentration, insulin resistance role should be considered.

Abstract

INTRODUCTION. Relationship between obesity and atherosclerosis development is well-documented. Among risk factors of atherosclerosis progression are both „old” and „new” — which clinical value is still intensively studied. In the pathogenesis of increased procoagulat state observed in obese patients potential role of plasminogen activator inhibitor 1 (PAI-1) is analysed. The aim of the study was to evaluate PAI-1 concentration and its relationship with selected anthropometric and biochemical parameters.
MATERIAL AND METHODS. 88 obese patients and 25 healthy subjects as a control were studied. Anthropometric parameters, concentrations of: fasting glucose, lipids, insulin with use of radioimmunomethric method, tumor necrosis factor alpha (TNFa) and PAI-1 with use of immunoenzymatic method were assessed. Insulin resistance in the participants was evaluated according to the homeostasis model assessment–insulin resistance (HOMA-IR) protocol.
RESULTS. Serum concentrations TNFa, PAI-1 and HOMA-IR index were significantly higher in the studied group as compared to the control. Positive correlation between insulin concentration, HOMA-IR and PAI-1 were found.
CONCLUSIONS. 1. Obese patients characterise increased activation of inflammatory process, procoagulant predisposition and insulin resistance. 2. In the pathogenesis of increased procoagulant activity in obese patients, observed in our study as elevated PAI-1 concentration, insulin resistance role should be considered.
Get Citation

Keywords

otyłość; inhibitor tkankowego aktywatora plazminogenu 1; insulinooporność; proces zapalny

About this article
Title

Evaluation of plasminogen activator inhibitor 1 concentration in patients with simple obesity

Journal

Endocrinology, Obesity and Metabolic Disorders

Issue

Vol 8, No 1 (2012)

Pages

1-7

Published online

2012-04-26

Page views

717

Article views/downloads

4930

Bibliographic record

Endokrynol. Otył. Zab. Przem. Mat 2012;8(1):1-7.

Keywords

otyłość
inhibitor tkankowego aktywatora plazminogenu 1
insulinooporność
proces zapalny

Authors

Paweł Bogdański
Monika Szulińska
Joanna Dytfeld
Danuta Pupek-Musialik

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk,

tel. +48 58 320 94 94, faks +48 58 320 94 94, e-mail:  viamedica@viamedica.pl